AR106475A1 - Derivados de piridina o de pirimidina - Google Patents
Derivados de piridina o de pirimidinaInfo
- Publication number
- AR106475A1 AR106475A1 ARP160103260A ARP160103260A AR106475A1 AR 106475 A1 AR106475 A1 AR 106475A1 AR P160103260 A ARP160103260 A AR P160103260A AR P160103260 A ARP160103260 A AR P160103260A AR 106475 A1 AR106475 A1 AR 106475A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- cyclopropyl
- piridine
- ethyl
- hydrogen
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- -1 1,1-dioxo-tetrahydro-thiophene-3-yl ring Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: R¹’ es metilo; R¹ es metilo, etilo, CF₃, CH₂OH, ciclopropilo o ciano, o R¹’ y R¹ juntos pueden formar un anillo 1,1-dioxo-tetrahidro-tiofen-3-ilo; R² es hidrógeno, metilo, etilo, isopropilo, tert-butilo, ciclopropilo, ciclopropilmetilo o hidroximetilo; R³ es Cl, F, CF₃, metilo, metoxi o ciclopropilo; R⁴ es hidrógeno, metilo, F o Cl; X es N o CH; Y es N o CH; con la condición de que X e Y no sean CH al mismo tiempo; o una sal farmacéuticamente aceptable o una sal de adición de ácido, una mezcla racémica o sus enantiómeros correspondientes y/o isómeros ópticos y/o estereoisómeros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15191887 | 2015-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106475A1 true AR106475A1 (es) | 2018-01-17 |
Family
ID=54360941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103260A AR106475A1 (es) | 2015-10-28 | 2016-10-26 | Derivados de piridina o de pirimidina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10155741B2 (es) |
| EP (1) | EP3368522B1 (es) |
| JP (1) | JP6849668B2 (es) |
| CN (1) | CN107922381B (es) |
| AR (1) | AR106475A1 (es) |
| TW (1) | TW201718539A (es) |
| WO (1) | WO2017072083A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6518789B2 (ja) | 2015-04-23 | 2019-05-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 精神障害の処置において使用するためのテトラゾール誘導体 |
| EP3359537B1 (en) | 2015-10-06 | 2020-03-25 | H. Hoffnabb-La Roche Ag | Triazole derivatives |
| EP3411365B1 (en) | 2016-02-02 | 2019-11-20 | H. Hoffnabb-La Roche Ag | Pyrazol-pyridine derivatives as eaat3 inhibitors |
| JP6936257B2 (ja) | 2016-05-27 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｅａａｔ３阻害剤としてのピラゾール化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2205573B1 (en) * | 2007-10-04 | 2013-10-23 | F. Hoffmann-La Roche AG | Tetrazole-substituted aryl amide derivatives and uses thereof |
| ES2534199T3 (es) * | 2008-10-31 | 2015-04-20 | Merck Sharp & Dohme Corp. | Antagonistas del receptor P2X3 para el tratamiento del dolor |
| JP6518789B2 (ja) * | 2015-04-23 | 2019-05-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 精神障害の処置において使用するためのテトラゾール誘導体 |
| EP3334727B1 (en) * | 2015-08-12 | 2019-05-15 | H. Hoffnabb-La Roche Ag | Pyridine and pyrimidine derivatives |
-
2016
- 2016-10-25 JP JP2018513843A patent/JP6849668B2/ja not_active Expired - Fee Related
- 2016-10-25 EP EP16793783.8A patent/EP3368522B1/en active Active
- 2016-10-25 WO PCT/EP2016/075590 patent/WO2017072083A1/en not_active Ceased
- 2016-10-25 CN CN201680050380.7A patent/CN107922381B/zh not_active Expired - Fee Related
- 2016-10-26 AR ARP160103260A patent/AR106475A1/es unknown
- 2016-10-27 TW TW105134681A patent/TW201718539A/zh unknown
-
2018
- 2018-04-17 US US15/954,964 patent/US10155741B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107922381A (zh) | 2018-04-17 |
| TW201718539A (zh) | 2017-06-01 |
| US10155741B2 (en) | 2018-12-18 |
| US20180258066A1 (en) | 2018-09-13 |
| EP3368522A1 (en) | 2018-09-05 |
| JP6849668B2 (ja) | 2021-03-24 |
| HK1247192A1 (zh) | 2018-09-21 |
| JP2018535926A (ja) | 2018-12-06 |
| EP3368522B1 (en) | 2021-08-04 |
| CN107922381B (zh) | 2020-10-13 |
| WO2017072083A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000666A1 (es) | Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo | |
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| AR109349A1 (es) | Compuestos y usos | |
| UY38057A (es) | Inhibidores de sarcómero cardíaco | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| AR114631A1 (es) | Métodos e intermedios para preparar compuestos de piridina | |
| CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR095011A1 (es) | Compuestos de antranilamida, sus mezclas y usos como plaguicidas | |
| AR104331A1 (es) | Derivados de tetrazol | |
| PE20180600A1 (es) | Inhibidores de metalo-beta-lactamasa | |
| AR111806A1 (es) | Derivados de indol n-sustituidos | |
| MX2022005615A (es) | Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo. | |
| AR103412A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| AR104528A1 (es) | Compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| NI202000058A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR106475A1 (es) | Derivados de piridina o de pirimidina | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
| MX388612B (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| CY1121147T1 (el) | Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου | |
| AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |